Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/16/2025 | $12.00 | Sector Outperform | Scotiabank |
| 3/14/2025 | Overweight | Cantor Fitzgerald | |
| 7/10/2023 | $22.00 | Buy | Guggenheim |
| 11/8/2021 | $32.00 → $34.00 | Outperform | Oppenheimer |
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patientsFavorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsOn track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), including data from patients who have reached the 12-month evaluation timepoint. The data will be featured during an interactive poster session at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2
TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposuresFavorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse eventsCompany to host conference call and webcast today at
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences: H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference. A fireside chat will take place on Tuesday, May 20, 2025 at 12:30 pm ET in New York.TD Cowen 6th Annual Oncology Innovation Summit. A fireside chat will take place virtually on Tuesday, May 27, 2025 at 1:30 pm ET. A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.prota
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in Q3 2025Strengthened leadership team with key appointments of Leonardo Viana Nicacio, M.D., as Chief Medical Officer, and Shane Williams, Ph.D., as VP, Head of Human Resources, Chief People Officer Cash, cash equivalents and investments of $158 million as of March 31, 2025, expected to support planned
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to six newly-hired employees. The independent members of Protara's Board of Directors approved the award from the Company's 2020 Inducement Plan, as amended (the "Inducement Plan") to Shane Williams, Protara's new Vice President, Head of Human Resources and Chief People Officer as an inducement material to his employment, in accordance with Nasdaq Listing Rule 56
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies. "We are delighted to welcome Dr. Nicacio to the Protara team," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "As a proven leader with deep expertise spanning all stages of drug development, his guida
- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021 Expected to Fund Operations into Mid-2024 - NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. "Following a productive 2021, we are well poised to advance our pipeline in 2022, in particular, we are excited to have commenced our Phase 1 study of TARA-002 in non-muscle invasive b
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer. "We are thr
Scotiabank initiated coverage of Protara Therapeutics with a rating of Sector Outperform and set a new price target of $12.00
Cantor Fitzgerald initiated coverage of Protara Therapeutics with a rating of Overweight
Guggenheim resumed coverage of Protara Therapeutics with a rating of Buy and set a new price target of $22.00
4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)